CalciMedica, Inc. (NASDAQ:CALC) Short Interest Down 9.3% in October

CalciMedica, Inc. (NASDAQ:CALC) saw a significant decline in short interest during the month of October. As of October 15th, there was short interest totalling 34,200 shares, a decline of 9.3% from the September 30th total of 37,700 shares. Based on an average daily trading volume, of 35,500 shares, the days-to-cover ratio is presently 1.0 days. Approximately 0.8% of the shares of the company are sold short.

Insider Transactions at CalciMedica

In other CalciMedica news, Director Robert N. Wilson purchased 54,000 shares of the stock in a transaction on Friday, August 23rd. The shares were purchased at an average price of $3.72 per share, with a total value of $200,880.00. Following the acquisition, the director now directly owns 364,196 shares of the company’s stock, valued at $1,354,809.12. This represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders acquired a total of 65,000 shares of company stock worth $243,120 over the last three months. 41.55% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have commented on CALC. Oppenheimer upped their target price on shares of CalciMedica from $14.00 to $20.00 and gave the company an “outperform” rating in a research report on Wednesday, July 10th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of CalciMedica in a research report on Tuesday, August 13th.

CalciMedica Trading Down 22.9 %

Shares of CALC stock opened at $3.70 on Friday. The firm’s fifty day moving average price is $4.27 and its two-hundred day moving average price is $4.64. CalciMedica has a 1 year low of $2.14 and a 1 year high of $8.38.

CalciMedica (NASDAQ:CALC) last issued its earnings results on Monday, August 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.03. On average, equities research analysts predict that CalciMedica will post -2.21 earnings per share for the current fiscal year.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.